IRAK4-IN-21

• CAT Number: I042859
• CAS Number: 2170694-04-7
• Molecular Formula: C28H28FN7O2
• Molecular Weight: 513.57
• Purity: ≥95%
• Synonyms: (1S,2S,3R,4R)-3-[[5-(5-fluoropyridin-3-yl)-2-[3-(pyrrolidine-1-carbonyl)anilino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide
• InChI: InChI=1S/C28H28FN7O2/c29-20-11-19(13-31-14-20)22-15-32-28(33-21-5-3-4-18(12-21)27(38)36-8-1-2-9-36)35-26(22)34-24-17-7-6-16(10-17)23(24)25(30)37/h3-7,11-17,23-24H,1-2,8-10H2,(H2,30,37)(H2,32,33,34,35)/t16-,17+,23+,24-/m1/s1
• InChIKey: KYNJAMYDYPTYDZ-GCRLEYHISA-N
• SMILES: C1CCN(C1)C(=O)C2=CC(=CC=C2)NC3=NC=C(C(=N3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)C6=CC(=CN=C6)F

IRAK4-IN-21（Cat No.:I042859）is a selective small molecule inhibitor that targets interleukin-1 receptor-associated kinase 4 (IRAK4), a key enzyme in the immune response. IRAK4 is involved in the activation of signaling pathways that lead to the production of pro-inflammatory cytokines, playing a crucial role in inflammation and immune system regulation. By inhibiting IRAK4, IRAK4-IN-21 aims to reduce excessive inflammation, offering potential therapeutic benefits in autoimmune diseases, chronic inflammation, and certain cancers. Preclinical studies suggest promising efficacy, and ongoing research is focused on optimizing its safety and clinical applications for immune-related disorders.